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xDBACKGROUND In animal models of heterotopic transplantation, mechanical unloading of the normal, nonhypertrophic
heart results in atrophy. Primarily on the basis of these animal data, the notion that chronic left ventricular assist
device (LVAD)-induced unloading will result in atrophy has dominated the clinical heart failure ﬁeld, and anti-atrophic
drugs have been used to enhance the cardiac recovery potential observed in some LVAD patients. However, whether
unloading-induced atrophy in experimental normal heart models applies to failing and hypertrophic myocardium in
heart failure patients unloaded by continuous-ﬂow LVADs has not been studied.
OBJECTIVES The study examined whether mechanical unloading by continuous-ﬂow LVAD leads to myocardial atrophy.
METHODS We prospectively examined myocardial tissue and hemodynamic and echocardiographic data from
44 LVAD patients and 18 untransplanted normal donors.
RESULTS Cardiomyocyte size (cross-sectional area) decreased after LVAD unloading from 1,238  81 mm2 to 1,011  68
mm2 (p ¼ 0.001), but not beyond that of normal donor hearts (682  56 mm2). Electron microscopy ultrastructural
evaluation, cardiomyocyte glycogen content, and echocardiographic assessment of myocardial mass and left ventricular
function also did not suggest myocardial atrophy. Consistent with these ﬁndings, t-tubule morphology, cytoplasmic
penetration, and distance from the ryanodine receptor were not indicative of ongoing atrophic remodeling during
LVAD unloading. Molecular analysis revealed no up-regulation of proatrophic genes and proteins of the ubiquitin
proteasome system.
CONCLUSIONS Structural, ultrastructural, microstructural, metabolic, molecular, and clinical functional data indicated
that prolonged continuous-ﬂow LVAD unloading does not induce hypertrophy regression to the point of atrophy and
degeneration. These ﬁndings may be useful in designing future investigations that combine LVAD unloading and phar-
maceutical therapies as a bridge to recovery of the failing heart. (J Am Coll Cardiol 2014;64:1602–12) © 2014 by the
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1603mechanical unloading of nonfailing and nonhyper-
trophic myocardium by means of: 1) heterotopic
transplantation (4); 2) LVAD (5); and 3) severing
the mitral papillary muscle chordae tendineae (6) sug-
gested that chronic unloading could lead tomyocardial
atrophy. Whether this phenomenon applies only to
unloaded nonfailing and nonhypertrophic myocar-
dium or also to hypertrophic and failing human
myocardium unloaded by continuous-ﬂow LVADs
is unknown. Available clinical data are inconclu-
sive and are limited to two human studies with
ﬁrst-generation, pulsatile LVADs that evaluated
left ventricular (LV) mass as assessed by echocar-
diography (7,8).SEE PAGE 1613
enzyme E2
UPS = ubiquitin proteasome
systemOn the basis of these limited animal and clinical
data, chronic LVAD unloading in patients with heart
failure (HF) was postulated to induce regression of
cardiac hypertrophy to the point of atrophy and
degeneration (8–12). This notion dominated the ﬁeld
to the point that speciﬁc anti-atrophic drugs (e.g.,
clenbuterol) were repeatedly used to prevent the
presumed atrophic remodeling in LVAD studies and
thus enhance the myocardial recovery observed in a
subset of patients during LVAD unloading (3,10–16).
In this prospective study, we investigated whether
mechanical unloading of the failing human heart
induced by continuous-ﬂow LVADs is associated with
myocardial atrophy and degeneration at the func-
tional, microstructural, ultrastructural, metabolic,
and molecular levels.
METHODS
STUDY POPULATION. We prospectively enrolled
44 consecutive patients with clinical characteristics
consistent with chronic HF who required circulatory
support with continuous-ﬂow LVAD as bridge to
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myocardial infarction, acute myocarditis,
post-cardiotomy cardiogenic shock, and so
on) were excluded. The patients were
enrolled at the institutions comprising the
UTAH Cardiac Transplant program (Univer-
sity of Utah Health Science Center, Inter-
mountain Medical Center, and the George E.
Wahlen VA Medical Center, Salt Lake City,
Utah). After LVAD implantation, the device
speed was adjusted to achieve adequate
ﬂows (cardiac output) and LV decompres-
sion. The pump speed was adjusted under
echocardiographic guidance during the
post-implantation hospitalization (and at
subsequent outpatient clinic visits) to
achieve a midline position at the interven-
tricular and interatrial septa and minimal mitral
valve regurgitation. Normal control samples were 18
normal donor hearts (mean age 33.6  3.5 years), not
allocated for heart transplantation for noncardiac
reasons (size, infection, etc.). The institutional re-
view board of the participating institutions approved
the study, and all patients provided informed
consent.
TISSUE ACQUISITION. Myocardial tissue was pro-
spectively collected from the LV apical core at LVAD
implantation. To avoid any reactive foreign body in-
ﬂammatory changes, tissue was obtained from the
apex at the time of cardiac transplantation, at least
1.5 to 2 cm distant from the LVAD inﬂow cannula site.
Control samples were acquired from hearts that were
not transplanted for noncardiac reasons. Normal
donor LV apical tissue was harvested and processed
in the same manner as the failing hearts. For tissue
processing details, see the supplemental Methods
section in the Online Appendix.
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TABLE 1 Baseline Clinical Characteristics of the Study
Population Before Left Ventricular Assist Device Implantation
Men 36 (82)
Age, yrs 51  2
Etiology
Ischemic cardiomyopathy 18 (41)
Nonischemic cardiomyopathy 26 (59)
New York Heart Association functional class
III 13 (30)
IV 31 (70)
Duration of heart failure history, yrs 6.6  1.2
Systolic arterial pressure, mm Hg 101  2
Diastolic arterial pressure, mm Hg 67  1.5
Serum concentrations
Brain natriuretic peptide, pg/ml 1692  215
Creatinine, mg/dl 1.4  0.1
Sodium, mmol/l 134  0.9
Hemoglobin, g/dl 12.4  0.3
Daily furosemide dose, mg 111  11
IABP 3 (6.8)
ECMO 1 (2.3)
Mean right atrial, mm Hg 12  1
Pulmonary capillary wedge, mm Hg 25  1.3
Systolic pulmonary arterial, mm Hg 54  2.6
Diastolic pulmonary arterial, mm Hg 28  1.6
Pulmonary vascular resistance, Woods units 3.6  0.5
Cardiac index, l$m–2$min–1 1.9  0.1
Values are n (%) or mean  SEM.
ECMO ¼ extracorporeal membrane oxygenation; IABP ¼ intra-aortic balloon
pump counterpulsation.
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in the Online Appendix.
ULTRASTRUCTURAL EVALUATION. Multiple optical
ﬁelds (8–10) of representative sections were exam-
ined for myocardial atrophic and degenerative char-
acteristics, and a combined scoring system was used
to validate both their severity and their extent (see
the supplemental Methods section in the Online
Appendix and Online Supplemental Methods Table 1
for details) (17).
ANALYSIS OF T-TUBULES AND RYANODINE RECEPTOR
DISTRIBUTION. Fresh, frozen heart sections were
labeled for t-tubule microstructure and ryanodine re-
ceptor (RyR) distribution and imaged with the use of a
Zeiss LSM 5 Duo confocal microscope (Zeiss) equipped
with a 63 oil immersion lens with a 1.4 numerical
aperture. Image stacks were processed as described
(18,19). Detailed descriptions of the tissue labeling,
imaging, and image analysis are in the supplemental
Methods section in the Online Appendix and Online
Supplemental Methods Figure 1.
MYOCARDIAL GLYCOGEN CONTENT EVALUATION.
Whole-s l ide d ig i ta l mic roscopy . As previously
described (17), we developed a whole-ﬁeld digital
microscopy method that allows estimation of
epicardium-to-endocardium myocardial glycogen
content by means of digital subtraction of adjacent
cardiac sections stained for periodic acid Schiff (PAS)
and PAS with diastase (PASD).
Biochemica l assay . Myocardial glycogen concen-
trationwasmeasured in mmol/gwet tissue as described
(20), normalized by myoglobin content (nmol/g wet
tissue weight), and presented as glycogen/myoglobin
in mmol/mg myoglobin (details in the supplemental
Methods section in the Online Appendix).
MICROARRAYS. With the use of the Illumina (San
Diego, California) platform, we measured and com-
pared the expression of genes involved in the
ubiquitin-proteasome system (UPS) in 20 paired
human heart samples (pre-LVAD and post-LVAD
unloading).
QUANTITATIVE REAL-TIME POLYMERASE CHAIN
REACTION. Total RNA was isolated with the use of
Trizol (Life Technologies, Carlsbad, California).
Synthesis of cDNA was performed with the use of
the Quantitec Reverse Transcription Kit (Qiagen,
Germantown, Maryland). Taqman primers (Life
Technologies) were used to perform quantitative
polymerase chain reaction (PCR). Quantiﬁcation was
performed with the use of the standard curve
method (see the supplemental Methods section in
the Online Appendix).WESTERN BLOTTING. Protein was extracted with the
use of lysis buffer supplemented with protease and
phosphatase inhibitors. Total protein lysates were
separated by SDS-PAGE and transferred to PVDF
membranes. Immunoblots were probed with the use
of antibodies against target proteins and developed
with the use of the ECL Plus Western blotting reagent
(GE Healthcare, Fairﬁeld, Connecticut) and Kodak
(Rochester, New York) Biomax MR ﬁlm (see the sup-
plemental Methods section in the Online Appendix).
E C HO CA R D I O G R A P H Y. Echocardiography labo-
ratories of the participating institutions performed
and stored serial echocardiographic examinations.
Echocardiographic studies included complete 2-
dimensional, M-mode, and Doppler examinations.
LV wall thickness; internal dimensions; their de-
rivatives, LV mass and fractional shortening; LV vol-
umes; and LV ejection fraction were obtained in
accordance with current American Society of Echo-
cardiography guidelines (21). Aortic valve opening
during three LV systoles was graded as full, inter-
mittent (one to two openings in three LV systoles), or
as full closure (22,23).
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1605STATISTICAL ANALYSIS. Values are expressed as
mean  SEM. Paired-samples Student t tests were
used for comparisons between pre-LVAD and post-
LVAD unloading. Independent-samples t tests were
used for comparisons between failing and normal
hearts. Signiﬁcance was considered at a value of
p < 0.05.
RESULTS
CLINICAL AND HEMODYNAMIC DATA. Table 1
shows patient demographic data, clinical character-
istics, and baseline hemodynamic data. Online
Supplemental Results Table 1 shows hemodynamic
measurements before and 2 months after LVAD
unloading. Left-sided and right-sided ﬁlling pres-
sures were signiﬁcantly decreased after 2 months of
LVAD support, suggesting that both ventricles were
unloaded after LVAD implantation. The degree of
ventricular mechanical unloading was assessed by
means of serial aortic valve opening evaluation at
representative time points (Online Supplemental
Results Figure 1) (22,23). Patients were medically
treated at the discretion of UTAH Cardiac Transplant
Program physicians. Medications used during LVAD
support included renin-angiotensin-aldosterone axisCENTRAL ILLUSTRATION No Signals for Disuse Atrophy
Forward and reverse cardiac remodeling during mechanical unloading ofinhibitors (n ¼ 12, 27%), beta-blockers (n ¼ 11, 25%),
loop diuretic agents (n ¼ 41, 93%), nitrates/hydral-
azine (n ¼ 12, 27%), calcium-channel blockers (n ¼
14, 44%), aspirin (n ¼ 43, 98%), clopidogrel (n ¼ 1,
2%), and warfarin (n ¼ 41, 93%).
STRUCTURAL DATA. After LVAD unloading, cross-
sectional area was signiﬁcantly decreased (1,238 
81 mm2 vs. 1,011  68 mm2; p ¼ 0.001), but not below
that of a normal heart (682  56 mm2) (Figure 1), which
would have suggested that LVAD unloading induces
hypertrophy regression to the point of atrophy. Re-
sults were similar in the subgroup of patients with
prolonged duration of mechanical unloading of
more than 6 months (Online Supplemental Results
Figure 2). Furthermore, our functional and struc-
tural echocardiographic data were also not indicative
of myocardial atrophy after 1 year of prolonged me-
chanical unloading (Table 2). The LV mass decreased
from 109 g/m2 to 104 g/m2 but did not drop below the
normal reference range (Table 2) (21).
ULTRASTRUCTURAL ELECTRON MICROSCOPY DATA.
No evidence was found of LVAD-induced atrophic
remodeling at the ultrastructural level. The ultra-
structural atrophy score in post-LVAD unloading
myocardial tissue samples was similar to the score inthe failing human heart induced by ventricular assist devices (VAD).
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FIGURE 1 Cardiomyocyte Size Evaluation
Representative photomicrographs of myocardial tissue stained with periodic acid Schiff
histochemical stain before left ventricular assist device (LVAD) implantation (A); after
LVAD support at the time of transplant (B); and from a normal heart (C). (D) Plots present
mean  SEM of cross-sectional area (n ¼ 44 heart failure patients, 5 normal donors). Scale
bar represents 50 mm.
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Results were also similar in the subgroup of patients
supported for a prolonged time period (>6 months).
DISTRIBUTION OF T-TUBULES AND RYR CLUSTERS.
Three-dimensional image stacks of tissue sections
show that the t-tubules are sparse, of simple topol-
ogy, and penetrate into the cell interior (Figures 3A to
3C). Local high-intensity RyR signals, indicative of
RyR clusters, were visible in regions closely proximal
to the sarcolemma (<0.5 mm) and in regions distant to
the sarcolemma. Statistical analyses of RyR signal
intensity grouped by sarcolemmal distance were
performed for 43 pre-LVAD implantation and 43 post-
LVAD implantation image stacks from tissue from 11
patients. Figure 3D presents the statistical analysis of
the image stack from Figure 3A. In this example,
35.8% of the RyR signal was in close proximity to the
sarcolemma. Figure 3E shows histograms for tissues
before and after LVAD implantation. The majority of
RyR intensity was in close proximity to the sarco-
lemma (59.2  3.2% and 58.2  3.3% for pre-LVAD
and post-LVAD, respectively). The pre-LVAD and
post-LVAD implantation RyR signal distances from
the sarcolemma were 0.66  0.04 mm and 0.64 0.04 mm, respectively (Figure 3F). We measured the
distance from the RyR signal to the sarcolemma after
grouping for the duration of LVAD support
(<6 months, >6 months). The distances were no
different in pre-LVAD and post-LVAD support (Online
Supplemental Results Figure 3).
MYOCARDIAL GLYCOGEN CONTENT. Atrophic myo-
cardium is characterized by increased glycogen
content (24,25). We measured the protein levels of
key glycogen synthesis pathway regulators and
found that the P-GSK-3b and total GSK3b (T-
GSK3b) remained unchanged after LVAD unloading
(Figure 4A). Similarly, myocardial glycogen content
assessed by whole-ﬁeld digital microscopy was un-
changed after LVAD unloading (Figures 4B to 4D) (26).
Direct glycogen content measurement by biochemical
assay conﬁrmed the latter ﬁnding, with results
normalized by myoglobin content to control for any
other myocardial changes induced by LVAD unload-
ing (Figure 4E). Results were similar in the subgroup
of patients supported for more than 6 months (Online
Supplemental Results Figure 4).
UBIQUITIN PROTEASOME SYSTEM. Cardiac atrophy
is associated with excessive protein degradation
(9,27). UPS is a major proteolysis pathway that is up-
regulated during atrophic remodeling of the heart
(9,27). With the use of microarrays, we compared
expression in the human heart before and after LVAD
unloading of atrial natriuretic peptide (ANP), B-type
natriuretic peptide, and 16 UPS genes. Whereas ANP
and B-type natriuretic peptide levels decreased after
LVAD unloading, consistent with hypertrophy regres-
sion (28), expression levels of the 16 UPS genes re-
mained unchanged (Online Supplemental Results
Table 2). With the use of quantitative real-time PCR,
we measured the transcript levels of ANP, ubiquitin
(UBB), ubiquitin-conjugating enzyme E2 (UBE2),
Atrogin 1, and Murf 1. Similar to the microarray gene
expression analysis, ANPmRNA levels were decreased
after LVAD unloading, whereas UBB, UBE2, MURF1,
and Atrogin 1 levels remained unchanged (Figure 5A,
Online Supplemental Results Figure 5A). Accordingly,
UBB, UBE2, and Atrogin 1 protein levels did not differ
signiﬁcantly between pre-LVAD and post-LVAD un-
loading (Figures 5B to 5D, Online Supplemental Results
Figures 5B to 5D). Of note, Murf 1 protein levels were
slightly decreased after LVAD unloading (Online
Supplemental Results Figure 5C). Finally, densitom-
etry analysis of ubiquitin conjugates showed the same
levels of protein ubiquitination in post-LVAD and pre-
LVAD tissue samples (Figure 5E). Results were similar
in the subgroup of patients supported for more than
6 months (Online Supplemental Results Figure 6).
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FIGURE 2 Electron Microscopy Ultrastructural Evaluation
Bars represent the quantiﬁcation of electron microscopy char-
acteristics indicative of myocardial atrophy and degeneration,
on the basis of our scoring system evaluating both the severity
(A) and the extent (B) of these characteristics (see Methods).
Differences between ultrastructural atrophy score in the post–
left ventricular assist device (LVAD) unloading myocardial tissue
samples and the pre-LVAD human myocardial tissue were not
signiﬁcant (n ¼ 9).
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1607DISCUSSION
To our knowledge, this is the ﬁrst study directly
investigating the effects of mechanical unloading
with a continuous-ﬂow LVAD on atrophic remodeling
of the failing human heart (Central Illustration). His-
tological analysis by whole-ﬁeld digital microscopy
showed reduction of myocyte cross-sectional area
after LVAD unloading, but not below that of the
normal heart, suggesting regression of cardiac hy-
pertrophy but not to the point of myocardial atrophy.
In agreement with this ﬁnding, serial echocardio-
graphic studies did not reveal any structural or func-
tional evidence compatible with myocardial atrophy
in patients with up to 1 year of mechanical unloading.
The electron microscopy ultrastructural evaluation
also did not show any changes indicative of ongoing
myocardial atrophy and degeneration after prolonged
continuous-ﬂow LVAD unloading. Similarly, 3-
dimensional confocal microscopy microstructural
analysis revealed no changes indicative of atrophic
remodeling in the relationship between t-tubules and
the RyR distribution. Finally, our metabolic and mo-
lecular analysis revealed no glycogen accumulation
and UPS system activation in the unloaded human
heart, which would have indicated ongoing myocar-
dial atrophy.
EFFECTS OF UNLOADING ON THE NORMAL AND
FAILING HEART. The physiologic myocardium is
characterized by load-induced plasticity. Thomson
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FIGURE 3 Analysis of T-Tubules and RyR Clusters in Tissue Sections
(A) Cross sections from image stack from confocal microscopy. Wheat germ agglutinin (blue) is used as a marker of sarcolemma and t-tubules.
Ryanodine receptor (RyR) clusters (red) were commonly close to the sarcolemma and t-tubules but were also found some distance from the
sarcolemma. Bar in A ¼ 20 mm. (B) Marked region in (A). Bar in B ¼ 5 mm. (C) Three-dimensional reconstruction of marked region in A with a
thickness of 3 mm. (D) Summary RyR intensity grouped by sarcolemmal distance. The histogram was calculated for the tissue section presented
in A. (E) The histogram was calculated from tissues before and after left ventricular assist device (LVAD) implantation. (F) Differences between
RyR-sarcolemmal distance before and after LVAD implantation were not signiﬁcant (n ¼ 11); other abbreviations as in Figure 1.
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1608et al. (6) ﬁrst showed that complete papillary muscle
unloading leads to atrophic remodeling. Animal
models of mechanical unloading by heterotopic
transplantation (4,29) or LVAD support (5) also
demonstrated an excessive reduction of myocyte size
within the ﬁrst month of unloading of the normal,
nonfailing heart.
Although the detrimental effect of prolonged
unloading on the normal heart has been well studied,
little is known about the effect of unloading on the
hypertrophic and failing heart. In a study of hetero-
topically transplanted hypertrophic rat hearts, 30
days of unloading resulted in reduction of LV mass
below the level of the normal heart (30). In contrast,
another study of heterotopically transplanted hyper-
trophic hearts showed reductions in myocyte cross-
sectional area and LV mass after unloading, but not
below the range of a normal heart (31). A limitation ofthe aforementioned animal studies is that they
investigated the effects of unloading on hearts that
had undergone hypertrophic stimuli for a short time
period. Thus, this model may not recapitulate prop-
erties of the end-stage failing and hypertrophic hu-
man heart that has progressively undergone cardiac
remodeling over many months or years. Also, the full/
complete mechanical unloading induced by the
standard animal model of heterotopic transplantation
is signiﬁcantly different (32–34) from the partial
unloading induced by LVAD (Online Supplemental
Results Figure 1 provides indirect clinical informa-
tion on the degree of mechanical unloading by LVAD).
Speciﬁc modiﬁcations to the standard heterotopic
transplantation animal model have been proposed to
address these issues and better simulate the me-
chanical unloading induced by cardiac assist devices
in the clinical arena (32–34).
Normal
Donors
Pr
e
Po
st
Pr
e
Po
st
Pre
LVAD
Post
Failing Hearts
Pre-Post LVAD Unloading
p=0.011
P-
GS
K3
b/
T-
GS
K3
b
(R
el
at
iv
e 
Fo
ld
 C
ha
ng
e)
Gl
yc
og
en
 / 
M
yo
gl
ob
in
(μμ
m
ol
/m
g)
Ca
rd
io
m
yo
cy
te
 G
ly
co
ge
n
Co
nt
en
t (
%
)
p=0.048
P-GSK3b
A
B C
ED
T-GSK3b
α-Actinin
p=ns
p=nsp=ns
Normal 
Donor
Normal 
Donor
1.5
1.0
0.5
0.0
40
40
30
20
10
0
50
30
20
10
0
Pre
LVAD
PostNormal 
Donor
Pre
LVAD
Post
FIGURE 4 Myocardial Glycogen Content Evaluation
(A) Immunoblot for P-GSK3b and T-GSK3b (n ¼ 26 heart failure [HF] patients, 9 normal donors); (B) representative myocardial image stained
with periodic acid Schiff (PAS); (C) adjacent slide stained with PAS with diastase (PASD). The combination of PAS and PASD was used to
demonstrate glycogen content with the use of our recently developed method (17). PAS stains cardiomyocyte glycogen stores and additional
tissue elements (neutral mucosubstances, epithelial sulfomucins, and sialomucins) magenta (26). PASD reaction digests glycogen with a
pretreatment of the tissue with a-amylase (depolymerizes glycogen) and, as a result, anymagenta staining here is solely attributed to the other
tissue elements mentioned in the preceding text (26). Glycogen stores can be evaluated by digital subtraction of the images derived from 2
adjacent slides stained with PAS and PASD (17). (D) Cardiomyocyte glycogen content (%) measured by means of digital subtraction of PAS-
PASD in corresponding annotated areas before and after LVAD implant (n ¼ 20 HF patients, 5 normal donors). (E) Cardiomyocyte glycogen
content directly measured by means of biochemical assay (level of glycogen normalized by myoglobin level in each individual sample) before
and after LVAD implant (n ¼ 5 HF patients, 4 normal donors). HF ¼ heart failure; P-GSK3b ¼ phosphorylated glycogen synthase kinase 3 beta;
T-GSK3b ¼ total glycogen synthase kinase 3 beta.
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1609In the clinical ﬁeld, a prospective multicenter trial
has shown a reduction in LV mass after pulsatile-ﬂow
LVAD support, as well as reduction in cardiomyocyte
size as assessed by standard histology (7). However,
no normal donor heart control group was included
in that study. In our study, we used continuous-ﬂow
LVADs that currently dominate the clinical arena
and also included normal donor hearts not allocated
to transplantation for non-cardiac reasons as a control
group; we found that myocyte cross-sectional area
decreased after LVAD unloading, but not below the
level of the normal donor heart. In addition, ourechocardiographic data (LV mass and functional
indices) were also not indicative of atrophy and
degeneration, even after 1 year of partial mechanical
unloading by continuous-ﬂow LVAD.
ATROPHIC REMODELING AND THE T-TUBULAR SYSTEM.
Recent evidence suggests that t-tubule microstruc-
ture is disrupted during myocardial atrophic remod-
eling. Speciﬁcally, with the use of 2-dimensional
microscopic imaging of isolated cardiac myocytes,
Ibrahim et al. (35) demonstrated that the atrophic
myocardium exhibited irregular t-tubular structure
and disarray of the t-tubular openings on the
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FIGURE 5 Effect of LVAD Unloading on the UPS
(A) Relative mRNA levels of ANP, UBB, and UBE2. ANP expression is decreased after LVAD unloading, whereas no change is observed for UBB
and UBE2 (n ¼ 20 HF patients, 9 normal donors). (B) Western blot of UBB, ubiquitin conjugates, and UBE2; densitometry analysis is shown of
immunoblot data for UBE2 (n ¼ 23 HF patients, 9 normal donors) (C), UBB (n ¼ 9 heart HF patients, 4 normal donors) (D), and UBB conjugates
(n ¼ 9 HF patients, 4 normal donors) (E). Protein levels of UBB conjugates, UBB, and UBE2 after LVAD unloading were not signiﬁcantly
different (C, D, E). ANP ¼ atrial natriuretic peptide; GAPDH ¼ glyceraldehyde-3-phosphate dehydrogenase; UBB ¼ ubiquitin; UBE2 ¼ ubiquitin-
conjugating enzyme E2.
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1610sarcolemma. These structural changes were associ-
ated with remodeling of calcium signaling, specif-
ically, increased occurrence of calcium sparks.
Atrophy was caused by 4 weeks of mechanical un-
loading of the normal and non-hypertrophic heart
by means of heterotopic abdominal transplantation
in a rat model (35). In contrast, unloading of failing
and hypertrophic hearts with the use of the same
approach and duration of unloading was associated
with partial restoration of the t-system (36). Partial
restoration of the t-system was associated with
partial restoration of calcium signaling (36).
In our study, we used confocal microscopy–based,
state-of-the-art, 3-dimensional image reconstruction
techniques (see Methods). We reconstructed the t-tu-
bule arrangement and provided quantitative data on
their relationship to RyR clusters (18,19). The t-system
was sparse and irregular (Figure 3A), as previously
shown for failing human ventricular myocytes (37).
We found that LVAD-induced partial unloading did
not alter the sparse t-tubule arrangement or the dis-
tance between RyRs and the sarcolemma (Figures 3Eand 3F). We found no indications of increased t-tu-
bule disarray after LVAD-induced partial unloading.
MOLECULAR MECHANISMS AND METABOLIC
EFFECTS OF ATROPHIC REMODELING. Myocardial
atrophy is characterized by increased cellular protein
degradation, with the UPS playing a central role
in regulation of this process (9,29). Speciﬁcally,
UBB-conjugating enzymes catalyze UBB binding to the
candidate protein for degradation. Ubiquitinated
proteins are recognized by the 19S subunit and are
degraded at the 20S subunit of the proteasome. During
atrophic remodeling of the heterotopically trans-
planted rat heart, UBB and UBE2 transcript levels are
signiﬁcantly increased (38). In another animal study,
induction of atrophy after full mechanical unloading
by heterotopic transplantation resulted in elevated
UBB and UBE2 protein levels as well as increased
ubiquitinated protein levels, suggesting up-regulation
of the UPS in the atrophic heart (4). In our study, we
did not detect differences in UBB and UBE2 gene
expression or protein levels after partial unloading by
the LVAD (Figure 5, Online Supplemental Results
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: The disuse at-
rophy that occurs in skeletal muscle does not appear to develop
when the hemodynamic load on failing human myocardium is
reduced through left ventricular assist device support.
TRANSLATIONAL OUTLOOK: Future research should explore
the mechanisms by which mechanical unloading enhances car-
diac recovery in patients with advanced ventricular failure.
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1611Table 2). Also, the E3 ubiquitin ligases, Atrogin 1 and
Murf 1, major indicators of proteolytic breakdown that
correlate with skeletal muscle atrophy, were not
up-regulated after continuous-ﬂow LVAD unloading
(Online Supplemental Results Figure 5) (39). However,
different types of mechanical unloading (e.g., pulsa-
tile vs. continuous-ﬂow) induce differential UPS
responses. Speciﬁcally, microarray studies investi-
gating gene expression changes induced by pulsatile
LVADs found up-regulation of the UPS (40,41). These
ﬁndings need to be conﬁrmed in studies that directly
compare the effects of these two types of unloading
on the UPS system. Such direct comparisons of pulsa-
tile versus continuous-ﬂow mechanical unloading
at the structural level revealed that the degree of
hypertrophy regression induced by pulsatile LVAD
unloading is similar to that induced by continuous-
ﬂow devices (42).
Elevated glycogen concentration was observed
both in rat skeletal muscle after disuse atrophy and in
rat atrophic myocardium induced by heterotopic
transplantation (27). Electron microscopy studies
of the atrophic rat heart also revealed excessive
glycogen accumulation (27). We assessed glycogen
levels in the human unloaded heart by means of
whole-ﬁeld digital microscopy and found unchanged
glycogen levels after LVAD unloading and conﬁrmed
these results by means of direct biochemical mea-
surement (20). These results suggest that myocar-
dium partially unloaded by the LVAD does not adopt
metabolic characteristics of atrophic myocardium.
STUDY LIMITATIONS. One limitation of our study is
the lack of human myocardial tissue derived from
patients undergoing mechanical unloading with
ﬁrst-generation, pulsatile LVADs, preventing direct
comparison of the effects of pulsatile versus
continuous-ﬂow devices on atrophic remodeling.
Another limitation is the lack of serial tissue evalu-
ation in the same patients, which would provide
useful information about the dynamics of the induced
hypertrophy regression during LVAD unloading. We
tried to address this limitation by investigating the
induced hypertrophy regression in patients with <6
months versus >6 months of continuous-ﬂow LVAD
unloading.CONCLUSIONS
Many groups have reported that cardiac function
can improve signiﬁcantly in a subset of patients
undergoing mechanical unloading (3,43,44). The
limited animal and clinical pulsatile LVAD data (8–12)
suggesting that chronic unloading in HF patients may
induce regression of cardiac hypertrophy to the point
of atrophy led to studies investigating whether spe-
ciﬁc anti-atrophic drugs (e.g., clenbuterol) enhance
LVAD-induced myocardial recovery (3,10–16). This
study adds new microstructural, ultrastructural,
metabolic, and molecular evidence that mechanical
unloading induced by continuous-ﬂow LVADs is not
associated with myocardial atrophy and degenera-
tion. These ﬁndings may be useful in designing
future investigations that combine pharmaceutical
therapies and LVAD unloading as a bridge to myo-
cardial recovery.
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